Deucravacitinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Deucravacitinib
DrugBank Accession Number
DB16650
Background

Deucravacitinib is under investigation in clinical trial NCT04772079 (A Study to Evaluate the Drug Levels, Efficacy and Safety of BMS-986165 in Adolescent Participants With Moderate to Severe Plaque Psoriasis).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 425.467
Monoisotopic: 425.200316838
Chemical Formula
C20H22N8O3
Synonyms
  • Deucravacitinib
External IDs
  • BMS-986165
  • WHO 11342

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Deucravacitinib hydrochloride95C5558CF41609392-28-0LILQGPVDQZORJG-NIIDSAIPSA-N

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
N0A21N6RAU
CAS number
1609392-27-9
InChI Key
BZZKEPGENYLQSC-FIBGUPNXSA-N
InChI
InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3
IUPAC Name
6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H3)methylpyridazine-3-carboxamide
SMILES
[2H]C([2H])([2H])NC(=O)C1=C(NC2=CC=CC(C3=NN(C)C=N3)=C2OC)C=C(NC(=O)C2CC2)N=N1

References

General References
Not Available
ChemSpider
72380005

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentPsoriasis1
3CompletedTreatmentPsoriasis2
3Not Yet RecruitingTreatmentPsoriatic Arthritis2
3RecruitingTreatmentPsoriasis2
3RecruitingTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
2Active Not RecruitingTreatmentSystemic Lupus Erythematosus (SLE)1
2CompletedTreatmentPsoriasis1
2CompletedTreatmentPsoriatic arthritis aggravated1
2Not Yet RecruitingTreatmentCrohn's Disease (CD) / Ulcerative Colitis1
2Not Yet RecruitingTreatmentDiscoid Lupus Erythematosus (DLE) / Lupus Erythematosus, Subacute Cutaneous1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.159 mg/mLALOGPS
logP1.8ALOGPS
logP2.1ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)11.09ChemAxon
pKa (Strongest Basic)2.38ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area135.95 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity138.38 m3·mol-1ChemAxon
Polarizability44.49 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on March 24, 2021 22:54 / Updated on March 26, 2021 04:01